BPG is committed to discovery and dissemination of knowledge
Case Report
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Dec 24, 2025; 16(12): 112140
Published online Dec 24, 2025. doi: 10.5306/wjco.v16.i12.112140
Radiotherapy for large ruptured hemorrhagic axillary lymph node metastasis from anaplastic lymphoma kinase-positive lung adenocarcinoma: A case report and review of literature
Zhi-Min Li, Yang-Chenxi Wang, Kai-Yue Wang, Ning-Jing Xie, Jun Zhou, Xiao-Na Chang, Quan Chen, Geng Wang, Sheng Zhang, Rui Zhou
Zhi-Min Li, , Department of Oncology, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan Province, 421001, China
Yang-Chenxi Wang, Kai-Yue Wang, Ning-Jing Xie, Sheng Zhang, Rui Zhou, Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China
Yang-Chenxi Wang, Kai-Yue Wang, Ning-Jing Xie, Sheng Zhang, Rui Zhou, Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China
Yang-Chenxi Wang, Kai-Yue Wang, Ning-Jing Xie, Sheng Zhang, Rui Zhou, Key Laboratory of Precision Radiation Oncology, Wuhan 430022 Hubei Province, China
Jun Zhou, Department of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China
Xiao-Na Chang, Department of Pathology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China
Quan Chen, Department of Radiology, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China
Geng Wang, Department of Gastrointestinal Surgery, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China
Co-first authors: Zhi-Min Li and Yang-Chenxi Wang.
Author contributions: Li ZM, Xie NJ, and Chen Q curated the data; Li ZM and Wang YC contributed equally to this manuscript as co-first authors; Wang YC, Zhou J, Chang XN and Wang KY confirmed the authenticity and accuracy of all the raw data; Wang YC created all the figures and tables; Xie NJ, Wang G, and Zhang S critically revised the manuscript; Zhang S and Zhou R made substantial contributions to the conception and design of the current study; Zhou R wrote the original draft of the manuscript. All authors have read and approved the final manuscript.
Supported by the National Natural Science Foundation of China, No. 82303833; the Open Research Fund of Hubei Key Laboratory of Precision Radiation Oncology, No. 2024ZLJZFL002; and the Science Foundation of Union Hospital, No. 2024ZLJZFL016.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Rui Zhou, Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Avenue, Wuhan 430022, Hubei Province, China. mimiruirui2@163.com
Received: July 21, 2025
Revised: August 20, 2025
Accepted: November 7, 2025
Published online: December 24, 2025
Processing time: 157 Days and 23.6 Hours
Abstract
BACKGROUND

Anaplastic lymphoma kinase (ALK) gene fusion is a molecular subtype of non-small cell lung cancer, representing 4%-6% of lung adenocarcinomas. Axillary lymph node (ALN) metastasis from lung cancer is rare, and massive bleeding from such lesions is an even more unusual and life-threatening complication. This case demonstrates how localized radiotherapy can be used as an effective hemostatic and tumor-controlling measure when conventional interventions fail.

CASE SUMMARY

A 48-year-old male presented in October 2019 with ALK-positive lung adenocarcinoma and multiple metastases. He received multiple lines of ALK tyrosine kinase inhibitor therapy, whole-brain radiotherapy, stereotactic radiotherapy, chemotherapy, and targeted agents over 4 years and 7 months. In February 2024, rapid enlargement and rupture of a left ALN metastasis caused massive bleeding. Interventional and surgical hemostasis were not feasible. Localized radiotherapy was initiated at 15 Gray in 5 fractions, later increased to a total of 39 Gray in 13 fractions, resulting in rapid bleeding control and partial tumor response. The patient subsequently received chemotherapy, and the axillary lesion healed without recurrent bleeding. However, three months later, he developed severe pneumonia with mixed bacterial, mycobacterial, and fungal infections and died despite intensive care.

CONCLUSION

Radiotherapy can effectively control bleeding and achieve local tumor control in ALK-positive lung cancer with ruptured ALN metastasis when other treatments are ineffective.

Keywords: Anaplastic lymphoma kinase fusion; Lung adenocarcinoma; Radiation therapy; Axillary lymph node metastasis; Bleeding; Case report

Core Tip: This case describes a patient with anaplastic lymphoma kinase-positive lung adenocarcinoma who developed massive bleeding from an axillary lymph node metastasis after resistance to multiple lines of targeted therapy. Localized radiotherapy achieved rapid hemostasis and effective local control when other interventions failed. The report discusses bleeding mechanisms, preventive strategies during radiotherapy, and the importance of multidisciplinary management. These findings provide practical guidance for treating rare but life-threatening complications in advanced lung cancer.